Labeling updates and warnings through November 2008 for efalizumab (Raptiva)
A boxed warning has been added to the labeling information for efalizumab (Raptiva, Genentech), which is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. This warning highlights the risk of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), occurring in patients treated with efalizumab. Infections that have been observed in efalizumab-treated patients include bacterial sepsis, viral meningitis, invasive fungal disease, PML, and other opportunistic infections.
Novo Nordisk Terminates Collaboration with Hims & Hers
June 23rd 2025The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded semaglutide products. Novo Nordisk said that Hims & Hers continues to offer these compounded drugs.
Read More